Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

In vitro and in vivo activity of melflufen (J1) in lymphoma

Authors: Maryam Delforoush, Sara Strese, Malin Wickström, Rolf Larsson, Gunilla Enblad, Joachim Gullbo

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years. Today it is part of standard therapy for multiple myeloma and also as part of myeloablative regimens in association with autologous allogenic stem cell transplantation. Melflufen (melphalan flufenamide ethyl ester, previously called J1) is an optimized derivative of melphalan providing targeted delivery of active metabolites to cells expressing aminopeptidases. The activity of melflufen has compared favorably with that of melphalan in a series of in vitro and in vivo experiments performed preferentially on different solid tumor models and multiple myeloma. Melflufen is currently being evaluated in a clinical phase I/II trial in relapsed or relapsed and refractory multiple myeloma.

Methods

Cytotoxicity of melflufen was assayed in lymphoma cell lines and in primary tumor cells with the Fluorometric Microculture Cytotoxicity Assay and cell cycle analyses was performed in two of the cell lines. Melflufen was also investigated in a xenograft model with subcutaneous lymphoma cells inoculated in mice.

Results

Melflufen showed activity with cytotoxic IC50-values in the submicromolar range (0.011-0.92 μM) in the cell lines, corresponding to a mean of 49-fold superiority (p < 0.001) in potency vs. melphalan. In the primary cultures melflufen yielded slightly lower IC50-values (2.7 nM to 0.55 μM) and an increased ratio vs. melphalan (range 13–455, average 108, p < 0.001). Treated cell lines exhibited a clear accumulation in the G2/M-phase of the cell cycle. Melflufen also showed significant activity and no, or minimal side effects in the xenografted animals.

Conclusion

This study confirms previous reports of a targeting related potency superiority of melflufen compared to that of melphalan. Melflufen was active in cell lines and primary cultures of lymphoma cells, as well as in a xenograft model in mice and appears to be a candidate for further evaluation in the treatment of this group of malignant diseases.
Literature
1.
Gilman A, Philips FS. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science. 1946;103(2675):409–15.CrossRef
2.
Haddow A, Kon GAR, Ross WCJ. Effects upon tumours of various haloalkylarylamines. Nature. 1948;162:824–5.CrossRef
3.
Bergel F, Stock JA. Cyto-active Amino-acid and Peptide Derivatives. Part I. Substituted Phenylalanines. J Chem Soc. 1954: 2409–17
4.
Bergel F, Stock JA. Cytotoxic alpha amino acids and peptides. Br Emp Cancer Camp Annu Rep. 1951;31:6–7.
5.
Bergel F, Burnop VCE Stock JA. Cyto-active Amino-acids and Peptides. Part II. Resolution of Substituted Phenylalanines and Synthesis of p-Di-(2-chloroethyl)amino-DL-phenyl[ß-14C]alanine. J Chem Soc. 1955:1223-9
6.
Bergel F, Stock JA. Cyto-active Amino-acids and Peptides. Part VIII. N(alpha)-Acyl, Amide, Ester and Peptide Derivatives of Melphalan. J Chem Soc. 1960:3658-69
7.
Furner RL, Brown RK. L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep. 1980;64(4-5):559–74.PubMed
8.
Teicher BA. Antitumor alkylating agents. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practise of Oncology (on CD-ROM). Philadelphia, Pennsylvania: Lippincott-Raven Publishers; 1997.
9.
Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Cancer Treat Res. 2002;112:305–22.CrossRefPubMed
10.
Sarosy G et al. The systemic administration of intravenous melphalan. J Clin Oncol. 1988;6(11):1768–82.CrossRefPubMed
11.
Bakshi N, Maghfoor I. The current lymphoma classification: new concepts and practical applications triumphs and woes. Ann Saudi Med. 2012;32(3):296–305.CrossRefPubMed
12.
13.
Wickström M et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79:1281–90.CrossRefPubMed
14.
Wickstrom M, Larsson R, Nygren P, et al. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102:501–8.CrossRefPubMed
15.
Gullbo J et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355–63.CrossRefPubMed
16.
Chauhan D, Ray A, Viktorsson K, et al. In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. Clin Cancer Res. 2013;19:3019–31.CrossRefPubMedPubMedCentral
17.
Gullbo J et al. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan. Anticancer Drugs. 2003;14(8):617–24.CrossRefPubMed
18.
Wickstrom M et al. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro. Invest New Drugs. 2008;26(3):195–204.CrossRefPubMed
19.
Gullbo J et al. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl- p -L-fluorophenylalanine ethyl ester (J1) in vivo. Invest New Drugs. 2004;22(4):411–20.CrossRefPubMed
20.
Wickstrom M et al. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther. 2007;6(9):2409–17.CrossRefPubMed
21.
Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther. 1999;83(2):67–123.CrossRefPubMed
22.
Wickstrom M et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281–90.CrossRefPubMed
23.
Kesler MV et al. Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol. 2007;128(2):314–22.CrossRefPubMed
24.
Dunphy CH et al. CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. J Clin Lab Anal. 2000;14(6):299–304.CrossRefPubMed
25.
Murata M et al. Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells. Leukemia. 1994;8(12):2188–93.PubMed
26.
Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26(1):88–130.CrossRefPubMed
27.
Larsson R et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992;50(2):177–85.CrossRefPubMed
28.
Csoka K et al. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol. 1994;54(2):163–70.CrossRefPubMed
29.
Nygren P et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia. 1992;6(11):1121–8.PubMed
30.
Lenz G et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633–43.CrossRefPubMedPubMedCentral
31.
Sambade C et al. U-2940, a human B-cell line derived from a diffuse large cell lymphoma sequential to Hodgkin lymphoma. Int J Cancer. 2006;118(3):555–63.CrossRefPubMed
32.
Huang PS, Oliff A. Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev. 2001;11(1):104–10.CrossRefPubMed
33.
Arimori S et al. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma. Tokai J Exp Clin Med. 1980;5(1):63–71.PubMed
34.
Ngo VN et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.CrossRefPubMed
35.
Morin RD et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–5.CrossRefPubMedPubMedCentral
36.
Kluin-Nelemans HC et al. A new non-Hodgkin’s B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia. 1991;5(3):221–4.PubMed
37.
Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma. 1993;9(1-2):1–25.CrossRefPubMed
38.
MacLeod RA et al. Karyotypic dissection of Hodgkin’s disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification. Leukemia. 2000;14(10):1803–14.CrossRefPubMed
39.
Kamesaki H et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin’s disease. Blood. 1986;68(1):285–92.PubMed
40.
Schaadt M et al. Two neoplastic cell lines with unique features derived from Hodgkin’s disease. Int J Cancer. 1980;26(6):723–31.CrossRefPubMed
41.
Kubonishi I et al. Characterization of a new human lymphoma cell line (RC-K8) with t(11;14) chromosome abnormality. Cancer. 1986;58(7):1453–60.CrossRefPubMed
42.
Tweeddale ME et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood. 1987;69(5):1307–14.PubMed
43.
Kubonishi I, Niiya K, Miyoshi I. Establishment of a new human lymphoma line that secretes plasminogen activator. Jpn J Cancer Res. 1985;76(1):12–5.PubMed
44.
Yee C et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989;74(2):798–804.PubMed
45.
Epstein AL et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer. 1978;42(5):2379–91.CrossRefPubMed
46.
Hecht BK et al. Histiocytic lymphoma cell lines: immunologic and cytogenetic studies. Cancer Genet Cytogenet. 1985;14(3-4):205–18.CrossRefPubMed
47.
Epstein AL, Kaplan HS. Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines. Cancer Res. 1979;39(5):1748–59.PubMed
48.
Amini RM et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 2002;43(11):2179–89.CrossRefPubMed
Metadata
Title
In vitro and in vivo activity of melflufen (J1) in lymphoma
Authors
Maryam Delforoush
Sara Strese
Malin Wickström
Rolf Larsson
Gunilla Enblad
Joachim Gullbo
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2299-9

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models

Research article

The circadian clock modulates anti-cancer properties of curcumin

Research article

Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours

Research article

PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

Research article

Dietary leucine supplementation minimises tumour-induced damage in placental tissues of pregnant, tumour-bearing rats

Research article

CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits